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OBJECTIVE — Tocomparetheefﬁcacyandsafetyoftherapid-actinginsulinanalogglulisine
and regular insulin in hyperglycemic hospitalized patients.
RESEARCHDESIGNANDMETHODS — Atotalof180hospitalizedpatientswithtype
2 diabetes received either glulisine (n  88) or regular insulin (n  92) before each meal in
combinationwithinsulinglargineatbedtimeinarandomizeddouble-blindfashion.Allprevious
diabetes medications were discontinued if applicable. Doses of insulin were adjusted to obtain
target blood glucose concentrations of 130 mg/dl before meals and at bedtime while avoiding
hypoglycemia.
RESULTS — Overallmeanbloodglucoseconcentrationswere8mg/dllowerintheglulisine
groupthanintheregularinsulingroup(152.666.6vs.160.470.8mg/dl;P0.0002).This
improvement was wholly due to 22 mg/dl lower levels after 4 days of therapy (140  55 vs.
16271mg/dl;P0.0007);afterday4,thisdifferenceprogressivelyincreasedsuchthatmean
blood glucose concentrations from day 7 onward were 31 mg/dl lower in the glulisine group.
Themeandailyincidenceofhypoglycemiawasslightlybutnotsigniﬁcantlylowerintheglulisine
than the regular insulin group (0.10  0.02 vs. 0.14  0.03 episode/day; P  0.35).
CONCLUSIONS — In hospitalized type 2 diabetic patients, glulisine may provide better
glycemic control than regular insulin, especially in those who have a prolonged length of stay.
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A
ccumulating evidence suggests that
hyperglycemiaisassociatedwithan
increased risk of complications and
mortality in hospitalized patients. In crit-
ically ill patients, improved glycemic
control reduces short- and long-term
mortality, rates of multiorgan failure, sys-
temic infections, and length of hospital-
ization (1–3). Likewise, in patients
admitted to general medical and surgical
areas hyperglycemia is associated with a
prolonged hospital stay, infection, dis-
ability, and death (4–6), suggesting that
poor glycemic control is associated with
poor clinical outcome.
Insulin is the most effective and the
most preferred agent for the treatment of
hyperglycemia in hospitalized patients
(7). However, inpatient insulin therapy is
often complicated by variable meal deliv-
ery, unpredictable food consumption,
and medical conditions, including liver
andkidneydisease,thatpredisposetohy-
poglycemia.Rapid-actinginsulinanalogs,
whichhavebeenshowntoreducetherisk
of hypoglycemia in the outpatient setting
(8), may hence be a better choice than
regularinsulinforthetreatmentofhyper-
glycemia in noncritically ill hospitalized
patients. The present study was therefore
undertaken to compare the efﬁcacy and
safety of the rapid-acting insulin analog
glulisine and regular insulin in hypergly-
cemic hospitalized patients.
RESEARCH DESIGN AND
METHODS— We enrolled 194 pa-
tients with type 2 diabetes who were ad-
mitted to a noncritical care medical or
surgical unit at the Carl T. Hayden VA
Medical Center (Phoenix, AZ). All pa-
tients were expected to stay hospitalized
3 days. Exclusion criteria included se-
vere hypoglycemia within the past 6
months or hypoglycemia unawareness
because of the known risk reduction of
hypoglycemia using rapid-acting insulin
analogs (9,10), prolonged nothing by
mouth status, continuous nutrition (total
parenteral nutrition or enteral nutrition),
and mental health conditions rendering
the patient unable to provide informed
written consent. Informed written con-
sent was obtained from all patients after
the study had been approved by the local
institutional review board.
All prior diabetes medications were
discontinued if applicable, and all pa-
tients were started on a basal-bolus insu-
lin regimen consisting of insulin glargine
(Lantus; sanoﬁ-aventis, Bridgewater, NJ)
and glulisine (Apidra; sanoﬁ-aventis,
Bridgewater, NJ) or regular insulin (No-
volin R, Novo Nordisk, Princeton, NJ).
Patients were assigned to receive glulisine
or regular insulin in a randomized dou-
ble-blind fashion. For patients treated
only with insulin before the hospitaliza-
tion, the initial dose of insulin was equal
to the total outpatient dose. For all other
patients, the initial total daily dose of in-
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1 if BMI was
25 kg/m
2, 0.5 IU/(kg   day)
1 if BMI
was25–30kg/m
2,and0.6IU/(kg day)
1
if BMI was 30 kg/m
2. One-half of the
total daily insulin dose was given as
glargine once daily at bedtime, and the
otherhalfwasgivenasglulisineorregular
insulin in equally divided doses before
breakfast, lunch, and dinner. All insulin
doses were administered by nurses, who
were not blinded to the study medica-
tions. Glulisine was administered imme-
diately before meals, regular insulin was
administered30minbeforemeals.Glu-
lisineandregularinsulinwerenotgivenif
a subject was unable to eat to avoid hypo-
glycemia. Fingerstick blood glucose
(FSBG) was tested daily before each meal,
at bedtime, and whenever subjects re-
ported symptoms of hypoglycemia; 2-h
postprandial and 2:00 A.M. FSBG were
tested every 3rd day starting on day 2 of
study participation. All FSBG measure-
ments were obtained using the Roche
Accu-Chek Inform glucose meter (Roche
Diagnostics, Indianapolis, IN) and down-
loaded to the VA Computerized Patient
Record System. Insulin doses were ad-
justed daily by the investigators (who
were blinded to the short-acting insulin)
to target blood glucose concentrations of
130 mg/dl before meals and at bedtime
while avoiding hypoglycemia using the
following guidance: for fasting blood glu-
cose concentrations of 130–160, 161–
200, and 200 mg/dl, increase glargine
by 10, 20, and 30%, respectively; for pre-
lunch,predinner,andbedtimebloodglu-
cose concentrations of 130–160, 161–
200, and 200 mg/dl, increase regular
insulin or glulisine at the prior meal by
10, 20, and 30%, respectively. Supple-
mental glulisine or regular insulin was
given in addition to the scheduled insulin
dose before each meal for blood glucose
concentrations 130 mg/dl according to
a sliding scale protocol (Table 1). Serum
creatinine, white blood cell count, and
A1Cweremeasuredonthe1stdayofhos-
pitalization. Fasting plasma C-peptide
with the concurrent plasma glucose con-
centration was measured on day 1 of
study participation. All measurements
wereperformedbytheCarlT.HaydenVA
Medical Center central laboratory using
standard assays.
Hypoglycemia was deﬁned as a blood
glucose concentration 60 mg/dl. Severe
hypoglycemia was deﬁned as an event
thatrequiredassistancefromanotherper-
son for recovery. Nocturnal hypoglyce-
mia was deﬁned as an event that occurred
between the injection of glargine at bed-
time and before the subject awoke in the
morning. As an index of -cell function,
homeostasis model assessment of percent
-cell function (HOMA-%B) was calcu-
lated as [fasting plasma insulin [pico-
moles per liter]  3.33/(fasting plasma
glucose [millimoles per liter] – 3.5)] (11).
The primary end points were glyce-
mic control, measured by the mean daily
blood glucose concentration, and the in-
cidence of hypoglycemia. Length of stay
was the secondary end point. Sample
sizes were calculated for 80% power at an
	of0.05forbothprimaryendpoints.We
assumed an average length of stay of 7
days, a within-group SD of 45 mg/dl in
mean daily blood glucose concentrations,
and a 30% incidence of subjects experi-
encing at least one episode of hypoglyce-
mia as found in a previous similar study
(12). Under these assumptions, power
calculations indicated the need for 80
subjects to detect a 10 mg/dl difference in
mean daily blood glucose concentrations
and the need for 565 subjects to detect a
25% difference in the incidence of hypo-
glycemia. However, before reaching the
latter sample size, at 194 subjects, the de-
cision was made to terminate the study
because of slower than expected enroll-
ment. Baseline characteristics of subjects
and outcome variables were compared
using the Student t test or the 

2 test as
appropriate. Multiple comparisons of
blood glucose concentrations over the
course of the subjects’ study participation
were performed using repeated-measures
ANOVA. Statistical analyses were per-
formed using the SPSS 16.0 (SPSS, Chi-
cago, IL). P  0.05 was considered
statisticallysigniﬁcant.Dataarepresented
as means  SD unless otherwise
indicated.
RESULTS
Patient characteristics
Ofthe194enrolledsubjects,96wereran-
domly assigned to glulisine and 98 were
randomly assigned to regular insulin.
Fourteen subjects dropped out for per-
sonal nonmedical reasons before receiv-
ing any insulin as part of this study: 8
subjects assigned to glulisine and 6 sub-
jects assigned to regular insulin. There-
fore,datafrom88subjectsintheglulisine
group and 92 subjects in the regular in-
sulin group were used for statistical anal-
yses. As shown in Table 2, both groups
were well matched for age, sex, BMI, pre-
viouslyunrecognizedtype2diabetes,and
prior history of type 2 diabetes, diabetes
duration, prior diabetes treatment, blood
glucose concentration on admission,
A1C, -cell function, renal function, and
white blood cell count. The most com-
mon admitting diagnoses were cardiovas-
cular disease, infection, and pulmonary
disease (Table 2). The length of time of
hospitalization was not signiﬁcantly dif-
ferent between the glulisine and the reg-
ular insulin group (7.3  0.5 vs. 8.4 
0.6 days; P  0.13).
Insulin doses
In the glulisine and the regular insulin
group,themeantotaldailydoseofinsulin
was similar (69  33 vs. 71  45 units;
NS) and was accounted for by a compa-
rable amount of short-acting insulin
(36  18 vs. 38  24 units; NS).
Glycemic control
During the entire period of the subjects’
study participation, mean blood glucose
concentrations were 8 mg/dl lower in
the glulisine group than in the regular in-
sulin group (152.6  66.6 vs. 160.4 
70.8 mg/dl; P  0.0002). This reduction
was wholly due to the on average 22
mg/dl lower blood glucose concentra-
tionsafter4daysoftherapy(14055vs.
162  71 mg/dl; P  0.0007), because
Table 1—Supplemental insulin sliding scale
Blood glucose
Insulin
BMI 25 kg/m
2 BMI 25–30 kg/m
2 BMI 30 kg/m
2
131–170 mg/dl 1 2 3
171–210 mg/dl 2 4 5
211–250 mg/dl 3 6 8
251–290 mg/dl 5 8 10
291–330 mg/dl 7 10 13
331–370 mg/dl 9 12 15
371 mg/dl 12 14 18
Data are units of insulin.
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groups during the ﬁrst 4 days (159  71
vs.15971mg/dl;P0.9).Afterday4,
the target blood glucose level of 130
mg/dl before meals was achieved in 48%
of subjects in the glulisine group and in
38% of subjects in the regular insulin
group(P0.0003);66%ofallbloodglu-
cose readings in the glulisine group were
90–180mg/dlcomparedwith54%inthe
regular insulin group (P  0.0001). The
difference in glycemic control between
both groups progressively increased such
that blood glucose concentrations from 7
day onward were 31 mg/dl lower in the
glulisine group (133  51 vs. 164  72
mg/dl; P  0.0001). The time course of
mean daily blood glucose concentrations
(premealandbedtimebloodglucosecon-
centrations) in both groups of subjects is
shown in Fig. 1A.
To examine whether the reduction in
glycemiabyglulisinecouldhavebeendue
to its direct actions, we separately ana-
lyzed blood glucose concentrations that
wereexpectedtobepredominantlydeter-
mined by the actions of glargine (e.g.,
fasting and 2:00 A.M. blood glucose con-
centrations) and blood glucose concen-
trations that were expected to be
predominantly determined by the actions
ofglulisineorregularhumaninsulin(e.g.,
prelunch, predinner, and bedtime blood
glucose concentrations, corresponding to
4-h postprandial levels and 2-h post-
prandial blood glucose concentrations).
When all blood glucose concentrations
throughout the study are used for analy-
sis, means of prelunch, predinner, and
bedtime blood glucose concentrations
(152  64 vs. 162  70 mg/dl; P 
0.0003) and 2-h postprandial blood glu-
cose concentrations (177  79 vs. 191 
77 mg/dl; P  0.03) were signiﬁcantly
lower in the glulisine group than in the
regular insulin group. In contrast, fasting
(141  59 vs. 140  57 mg/dl) and 2:00
A.M.bloodglucoseconcentrations(149
67 vs. 150  67 mg/dl) were virtually
identical in both groups (both P  0.7)
(Fig. 1B). Similar results were obtained
when only blood glucose concentrations
past day 4 were examined. Prelunch,
predinner, and bedtime blood glucose
concentrations (138  51 vs. 162  72
mg/dl; P  0.000002) and 2-h postpran-
dial blood glucose concentrations (164 
70 vs. 191 71 mg/dl;P  0.0026) were
signiﬁcantly lower in the glulisine group
than in the regular insulin group whereas
fasting (125  49 vs. 141  54 mg/dl;
P  0.06) and 2:00 A.M. blood glucose
concentrations (150  52 vs. 160  67
mg/dl; P  0.8) were not signiﬁcantly
different.
Subgroup analysis
To examine whether the improved glyce-
miawithglulisinepastday4couldpoten-
tially be explained by different
characteristics of subjects who stayed
hospitalized for a longer period of time,
we compared subjects participating 4
days (n  39 in the glulisine group; n 
54 in the regular insulin group) with sub-
jects participating 4 days in separate
analyses. Age, sex, BMI, A1C, HOMA-
%B, diabetes duration, and admission di-
agnosis were comparable between these
subgroupsinboththeglulisinegroupand
the regular insulin group (all P  0.3).
Moreover, in subjects who participated
4 days, glycemic control was similar in
theglulisineandtheregularinsulingroup
during the ﬁrst 4 days of study participa-
tion(P0.9)asfoundwhenweanalyzed
data for all subjects.
Hypoglycemia
Throughoutthestudy,therewere123hy-
poglycemic events: 56 in the glulisine
groupand67intheregularinsulingroup.
However, neither the number of subjects
with one or more hypoglycemic episodes
(30 vs. 35%; P  0.5) nor the average
daily incidence of hypoglycemia was sig-
niﬁcantly different (0.10  0.02 vs.
0.140.03 episode/day;P0.35). Fur-
thermore, the incidence of hypoglycemia
was not signiﬁcantly different between
both groups during the ﬁrst 4 days of
therapy (0.11  0.03 vs. 0.14  0.03 ep-
isode/day; P  0.4), during which glyce-
mia was comparable, and after day 4
(0.07  0.02 vs. 0.06  0.02 episode/
day;P0.6),duringwhichglycemiawas
signiﬁcantly reduced in the glulisine
group. The severity and the time of day of
hypoglycemic events were also similar in
bothgroups(Table3).Onlyonehypogly-
cemic event, which occurred in the regu-
lar insulin group, was severe.
CONCLUSIONS — In hospitalized
patients, hyperglycemia is a frequent,
serious, and costly problem, and tight
Table 2—Baseline clinical and biochemical characteristics of the study groups
Regular insulin Glulisine
n 92 88
Age (years) 65.1  9.1 65.6  10.1
Sex (male/female) 91/1 87/1
BMI (kg/m
2) 32.1  7.0 32.6  7.6
Race/ethnicity (white/black/Hispanic) 72/10/10 64/12/12
Unrecognized type 2 diabetes 4 (4) 2 (2)
History of type 2 diabetes 88 (96) 86 (98)
Diabetes duration (years) 11.9  8.0 11.6  8.8
Diabetes treatment before hospitalization
No pharmacological agents 5 (5.4) 3 (3.4)
Oral agent monotherapy 12 (13) 22 (25)*
Multiple oral agents 13 (14) 18 (20)
Insulin plus oral agents 34 (37) 27 (31)
Insulin only 28 (30) 18 (20)
A1C (%) 7.7  1.7 7.7  1.8
HOMA-%B 1.03  0.95 0.96  1.06
Admission blood glucose (mg/dl) 189  86 187  95
White blood cell count  10
6 10.4  4.6 10.1  4.4
Serum creatinine (mg/dl) 1.6  1.3 1.6  1.3
Admission diagnosis (%)
Cardiovascular disease 30 (32) 30 (34)
Infection 23 (25) 18 (20)
Pulmonary disease 11 (12) 9 (10)
Uncontrolled diabetes 1 (1) 1 (1)
Renal disease 1 (1) 3 (3)
Amputation/diabetic foot ulcer 7 (8) 5 (6)
Other 19 (21) 22 (25)
Data are means  SD or n (%). To convert the values for glucose from milligrams per deciliter to millimoles
per liter, multiply by 0.05551. *P  0.05.
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American Diabetes Association (7). The
present trial is the ﬁrst to compare the ef-
ﬁcacy and safety of the rapid-acting insu-
lin analog glulisine and regular insulin in
hospitalizedpatientswithtype2diabetes.
Using a randomized double-blind study
design, we found that treatment with glu-
lisine resulted in lower blood glucose
concentrations than treatment with regu-
lar insulin without increasing the risk of
hypoglycemia. When all blood glucose
readings during the study are considered,
thereductioninglycemiabyglulisinewas
8 mg/dl. This reduction was highly sig-
niﬁcant but arguably modest. However, if
only data past day 4 of therapy are con-
sidered, glulisine resulted in 22 mg/dl
reduced blood glucose concentrations,
because both groups had similar levels
duringtheﬁrst4days.Thereafter,thedif-
Table 3—Frequency and severity of hypoglycemia
Regular insulin Glulisine
Hypoglycemic episodes 67 56
Blood glucose 50–59 mg/dl 40 34
Blood glucose 40–49 mg/dl 19 17
Blood glucose 40 mg/dl 8 5
Subjects with 1 hypoglycemic episode 32 26
Incidence of hypoglycemia (episodes/day) 0.136  0.027 0.103  0.020
Data are n or means  SD.
Figure1—A:Timecourseofmeandailybloodglucoseconcentrations(premealandbedtimebloodglucoseconcentrations)inpatientstreatedwithglulisine
(f)orregularinsulin( )incombinationwithglargine.Numbersontopofeachbarindicatethenumberofsubjectsineachgroup.DataaremeansSEM.
Overall ANOVA, P0.0001. B: Mean blood glucose concentrations prebreakfast (PRE-B), 2-h postbreakfast (POST-B), prelunch (PRE-L), 2-h postlunch
(POST-L), predinner (PRE-D), 2-h postdinner (POST-D), at bedtime, and at 2:00 A.M. in patients treated with glulisine (F) or regular insulin (E)i n
combination with glargine during the entire study. Means of prelunch, predinner, and bedtime blood glucose concentrations (P  0.0003) and 2-h
postprandial blood glucose concentrations (P  0.03), largely determined by the short-acting insulin, were signiﬁcantly lower in the glulisine group than
intheregularinsulingroup.Incontrast,fastingand2:00 A.M.bloodglucoseconcentrations,largelydeterminedbyglargine,werecomparableinbothgroups
(both P  0.7). Data are means  SEM.
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increasedsuchthatafter7daysbloodglu-
cose concentrations were 31 mg/dl
lower in the glulisine group.
Itisofnotethatsubjectsparticipating
for 4 days did not differ from those par-
ticipating for 4 days in demographic,
physical, and medical characteristics and
that glycemic control was similar in the
glulisine and the regular insulin group
during their ﬁrst 4 days of study partici-
pationaswehadfoundwhenweanalyzed
data for all subjects. Furthermore, the in-
cidenceofhypoglycemiawas,ifanything,
slightly higher in the regular insulin
group than in the glulisine group. These
ﬁndings suggest that the improvement in
glycemic control by glulisine after but not
during the ﬁrst 4 days of therapy was due
to the length of time required for dose
titration and not due to unique character-
istics of subjects who were hospitalized
for a longer period of time. Moreover,
they denote that insulin was titrated at
least equally aggressively in the regular
insulin group as in the glulisine group by
the blinded investigators, suggesting that
development of hypoglycemia prevented
further up-titration of regular insulin and
achievement of glycemic control similar
to that in the glulisine group and that, for
a given aggressiveness in dose titration
with similar frequency of hypoglycemia,
glulisine may provide better glycemic
control than regular insulin in hospital-
ized patients with type 2 diabetes.
The results of the present study are
verymuchconsistentwiththoseofDailey
et al. (8) in that twice-daily glulisine in
combination with NPH insulin improves
glycemic control without increasing the
frequency of hypoglycemia in outpatient
type 2 diabetic patients. In contrast, our
results disagree somewhat with those of
Umpierrez et al. (12) in hospitalized pa-
tients with type 2 diabetes. In this study,
the insulin analogs detemir given once
daily and aspart given before meals re-
sulted in glycemic control and frequency
of hypoglycemia similar to that with a
split-mixed regimen with NPH and regu-
lar insulin despite use of a dose titration
schedule similar to that in the present
study. However, contrary to our study,
subjectswereyoungerandwereexcluded
forclinicallyrelevantliverandkidneydis-
ease, suggesting that differences in study
populations, speciﬁcally the risk of hypo-
glycemia, may be an explanation for the
differing results.
In the present study both groups of
subjects were well matched for age, dia-
betes duration, prior diabetes treatment,
prior glycemic control, -cell function,
renal function, and white blood cell
count. Furthermore, the study personnel,
making adjustments to the insulin doses,
was blinded to the short-acting insulin.
Only nurses, who administered the insu-
lin, were unblinded to the types of short-
acting insulin because of the different
administration times in relation to meals.
Therefore, differences in subjects’ charac-
teristics between the glulisine and regular
insulin groups or bias of the investigators
is an unlikely explanation of our results.
Nevertheless, we acknowledge the fol-
lowing limitations of our study. First, it
was performed in a single center in an
elderly veteran population involving
nearly exclusively males. Thus, whether
the results can be generalized to other
hospitalsettingsandpopulationsneedsto
be examined. Second, only individuals
highly trained in insulin treatment made
adjustments in insulin doses, and blood
glucose levels were carefully reviewed at
leastonceaday,exceedingtheusualstan-
dard of care. Therefore, whether treat-
ment with glulisine provides superior
control compared with regular insulin in
hospitalized patients in the hands of less
well-trained providers and with less care-
fulbloodglucosemonitoringmayneedto
betested.Third,itispossiblethatsomeof
our study patients were not completely
blinded regarding the type of mealtime
insulin because of their knowledge of the
different administration times of regular
insulin and glulisine relative to meals.
And fourth, we unfortunately did not
achieve our estimated sample size needed
for detecting differences in the incidence
of hypoglycemia because of slower than
expected patient recruitment.
Incriticallyillpatients,hypoglycemia
hasbeenfoundtobeassociatedwithpoor
clinical outcome (13). Although the cau-
sality of hypoglycemia leading to poor
clinical outcome has been questioned
(14), hypoglycemia or the fear of it in
health care providers and patients is un-
doubtedly the major barrier for the con-
trolofglycemia.Inthepresentstudy,30–
35% of patients experienced at least one
episode of hypoglycemia with an inci-
denceof0.1–0.14episode/day,compa-
rable to the rates of hypoglycemia in the
previoussimilarstudybyUmpierrezetal.
(12). This observation demonstrates the
difﬁculty of achieving tight glycemic con-
trol and underscores the importance of
improving our treatment modalities in
hospitalizedpatientswithtype2diabetes.
In summary, the present study pro-
vides evidence suggesting that treatment
with glulisine can provide superior glyce-
mic control compared with regular insu-
lin in hospitalized patients with type 2
diabetes, especially in those who have a
prolonged length of stay. Further studies
are needed to examine whether these re-
sults can be generalized to other popula-
tions and hospital settings, and whether
thebeneﬁtsofglulisineperseverewiththe
usual standard of care for glycemic
control.
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